GSK vs SUPN · P/E 13, $103.31B cap vs rev $426.8M
GlaxoSmithKline PLC ADR (GSK) versus Supernus Pharmaceuticals Inc (SUPN) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Supernus Pharmaceuticals Inc (SUPN) is a drug manufacturers - specialty & generic company listed on NASDAQ.
GSK does not have a complete income-statement cache yet.
Latest reported SUPN revenue for 2026-06-30 was $426.8M. Net income was -$60.7M. SUPN currently screens at market cap $2.53B.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. SUPN currently screens at market cap $2.53B.
Not investment advice. Open the GSK and SUPN stock pages for the full models.
Not investment advice.